Print

3BNC117-LS

A Phase 1, Dose Escalation, First-in-human Study of the Safety and Pharmacokinetics of 3BNC117-LS Administered Intravenously in HIV-infected and HIV-uninfected Individuals

Trial Details:

I Ongoing
Rockefeller University August 01, 2017
3BNC117-LS 3BNC117-LS antibody with?aa mutations, M428L and N434S, in the?Fc domain??? ???
3BNC117-LS Passive Immunization
USA 30
NCT03254277
https://www.clinicaltrials.gov/ct2/show/NCT03254277